Quality assurance of drugs used in clinical trials: proposal for adapting guidelines
暂无分享,去创建一个
P. Newton | F. T. Ter Kuile | D. Schellenberg | E. Ashley | N. White | P. Guérin | R. Ravinetto | P. Tabernero | M. Green | F. T. ter Kuile
[1] J. Wyatt,et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide , 2014, BMJ : British Medical Journal.
[2] Isabelle Boutron,et al. Timing and Completeness of Trial Results Posted at ClinicalTrials.gov and Published in Journals , 2013, PLoS medicine.
[3] David Moher,et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials , 2013, BMJ.
[4] P. Newton,et al. The Primacy of Public Health Considerations in Defining Poor Quality Medicines , 2011, PLoS Medicine.
[5] Raffaella Ravinetto,et al. Quality of medical devices and in vitro diagnostics in resource‐limited settings , 2011, Tropical medicine & international health : TM & IH.
[6] Trudie Lang,et al. Clinical research: time for sensible global guidelines , 2011, The Lancet.
[7] Jeremy Howick,et al. What's in Placebos: Who Knows? Analysis of Randomized, Controlled Trials , 2010, Annals of Internal Medicine.
[8] L. Slutsker,et al. Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria , 2009, Malaria Journal.
[9] P. Bossuyt,et al. Standards for Reporting on Diagnostic Accuracy Studies , 2009 .
[10] C. Mace,et al. Substandard medicines in resource‐poor settings: a problem that can no longer be ignored , 2008, Tropical medicine & international health : TM & IH.
[11] H. Mshinda,et al. Randomized controlled safety and efficacy trial of 2 vitamin A supplementation schedules in Tanzanian infants. , 2007, The American journal of clinical nutrition.
[12] Paul N Newton,et al. Counterfeit anti-infective drugs. , 2006, The Lancet. Infectious diseases.
[13] David Moher,et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. , 2004, Family practice.
[14] F. Sörgel,et al. Lack of bioequivalence of a generic mefloquine tablet with the standard product , 1998, European Journal of Clinical Pharmacology.
[15] C. Csillag. Epidemic of counterfeit drugs causes concern in Brazil. , 1998, Lancet.
[16] C. Csillag. SÃO PAOLO Epidemic of counter feit drugs causes concern in Brazil , 1998, The Lancet.
[17] L. Salako,et al. Bioavailability of sulphate and dihydrochloride salts of quinine. , 1994, African journal of medicine and medical sciences.
[18] D G Altman,et al. The hidden effect of time. , 1988, Statistics in medicine.
[19] T. R. Shaw. The digoxin affair , 1974 .
[20] 黄亚明(整理),et al. Equator network , 2012 .
[21] D. Barends,et al. Biowaiver monographs for immediate release solid oral dosage forms: mefloquine hydrochloride. , 2011, Journal of pharmaceutical sciences.
[22] J. Abraham. The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use , 2009 .
[23] I R König,et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. , 2003, Clinical chemistry.
[24] T. R. Shaw. Trade names or approved names. Part III. Special cases. The digoxin affair. , 1974, Postgraduate medical journal.